{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.45","upperLimit":"4.47","value":"4.47"},{"comment":"NA=Not calculable due to insufficient response events","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"9.92"},{"comment":"NA=Median was not reached (max value was 58.22)","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"NA=Median was not reached (max value was 58.22)","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"NA=Not calculable due to insufficient response events","groupId":"OG004","lowerLimit":"14.6","upperLimit":"NA","value":"34.83"},{"comment":"NA=Not calculable due to insufficient response events","groupId":"OG005","lowerLimit":"15.0","upperLimit":"NA","value":"29.01"},{"comment":"NA=Not calculable due to insufficient response events","groupId":"OG006","lowerLimit":"18.2","upperLimit":"NA","value":"29.24"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"36"},{"groupId":"OG005","value":"37"},{"groupId":"OG006","value":"73"}],"units":"Participants"}],"description":"Duration of response is defined as the time from the initial objective response to disease progression or death, whichever occurs first. The distribution of duration of response was estimated for each treatment group using Kaplan-Meier methodology. Point estimates and 95% CIs for the median for the duration of response distribution are provided.","dispersionType":"95% Confidence Interval","groups":[{"description":"Elotuzumab 5 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.","id":"OG000","title":"Elotuzumab 5 mg/kg + Lenalidomide and Dexamethasone (Phase 1)"},{"description":"Elotuzumab 10 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.","id":"OG001","title":"Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 1)"},{"description":"Elotuzumab 20 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.","id":"OG002","title":"Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 1)"},{"description":"Elotuzumab (5, 10, or 20 mg/kg) administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.","id":"OG003","title":"Total (Phase 1)"},{"description":"Elotuzumab 10 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.","id":"OG004","title":"Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 2)"},{"description":"Elotuzumab 20 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.","id":"OG005","title":"Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 2)"},{"description":"Elotuzumab (10 or 20 mg/kg) administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally","id":"OG006","title":"Total (Phase 2)"}],"paramType":"MEDIAN","populationDescription":"Safety population: All randomized participants who received at least 1 dose of study drug","reportingStatus":"POSTED","timeFrame":"From first dose of elotuzumab (phase 1) or randomization (phase 2) until 60 days following the last infusion (or before initiation of new therapy), up to 101 months","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}